Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7644350 | 0.78 | — | — | |
| SCHEMBL24640 | 0.74 | PI4KA (0.50) | — | |
| Ammonia Solution, Strong SCHEMBL28104176 | 0.72 | PI4KA (0.48) | — | |
| SCHEMBL29559610 | 0.67 | LMNA (0.57) | DYRK1AALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL9082 | 0.67 | LMNA (0.57) | DYRK1AALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL30834859 | 0.65 | LMNA (0.55) | DYRK1AALDH1A1MAPK1MEN1KMT2A | |
| Water SCHEMBL27775008 | 0.65 | LMNA (0.55) | DYRK1AALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL9798930 | 0.65 | LMNA (0.55) | DYRK1AALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL3445227 | 0.65 | CHEK1 (0.37) | DYRK1A | |
| SCHEMBL6016629 | 0.65 | EGLN1 (0.43) | DYRK1AEGLN1KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3565817-B1 | SMALL MOLECULE INHIBITORS OF NEUTRAL SPHINGOMYELINASE 2 (NSMASE2) FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIV JOHNS HOPKINS (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11427590-B2 | Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) for the treatment of neurodegenerative diseases | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-08-30 | — | — | US | disclosed |
| US-20200190089-A1 | SMALL MOLECULE INHIBITORS OF NEUTRAL SPHINGOMYELINASE 2 (NSMASE2) FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) | 2020-06-18 | — | — | US | disclosed |
| EP-3565817-A1 | SMALL MOLECULE INHIBITORS OF NEUTRAL SPHINGOMYELINASE 2 (nSMase2) FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | The Johns Hopkins University (US) | 2019-11-13 | — | — | EP | disclosed |
| WO-2018129405-A1 | SMALL MOLECULE INHIBITORS OF NEUTRAL SPHINGOMYELINASE 2 (nSMase2) FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-07-12 | — | — | WO | disclosed |
| US-7816350-B2 | Substituted [1,2,3] triazolo[4,5-D]pyrimidines as cdk inhibitors | INSTITUTE OF EXPERIMENTAL BOTANY ASCR (CZ) | 2010-10-19 | — | — | US | disclosed |
| US-20070208038-A1 | 6-(2-Fluorophenyl)-Triazolopyrimidines, Method for Producing Them, Their use for Controlling Parasitic Fungi and Agents Containing the Same | BASF AKTIENGESELLSCHAFT (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7217815-B2 | 2-beta -modified-6-substituted adenosine analogs and their use as antiviral agents | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2007-05-15 | — | — | US | disclosed |
| US-20060183706-A1 | 2-Beta-modified-6-substituted adenosine analogs and their use as antiviral agents | BAUSCH HEALTH IRELAND LIMITED (IE) | 2006-08-17 | — | — | US | disclosed |
| US-20060035909-A1 | 2,6,9-trisubstituted 8-azapurines such as 2-(4-aminocyclohexylamino)-6-benzylamino-9-isopropyl-8-azapurine, used as cyclin-dependent kinase inhibitors, in the treatment of skin disorders, viral infections, cancer, arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, gout | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2006-02-16 | — | — | US | disclosed |
| EP-1539760-A2 | AZAPURINE DERIVATIVES | INSTITUTE OF EXPERIMENTAL BOTANY ASCR (CZ) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004018473-A2 | AZAPURINE DERIVATIVES | INSTITUTE OF EXPERIMENTAL BOTANY ASCR (CZ) | 2004-03-04 | — | — | WO | disclosed |
| WO-2003062256-A1 | 2'-BETA-MODIFIED-6-SUBSTITUTED ADENOSINE ANALOGS AND THEIR USE AS ANTIVIRAL AGENTS | RIBAPHARM INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| US-4739053-A | CHARGE CARRIER-TRANSPORTING COMPOUNDS; ELECTROGRAPHY | BASF AKTIENGESELLSCHAFT (DE) | 1988-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208038-A1 | 6-(2-Fluorophenyl)-Triazolopyrimidines, Method for Producing Them, Their use for Controlling Parasitic Fungi and Agents Containing the Same | CBR1, CBR3, DPM1 | DYRK1A 2614/4885EGLN1 101/4885KDM4E 3090/4885 |
| US-11427590-B2 | Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) for the treatment of neurodegenerative diseases | SMPD2, SPTLC2, SGMS2 | DYRK1A 4576/4885EGLN1 3329/4885KDM4E 1529/4885 |
| US-20060183706-A1 | 2-Beta-modified-6-substituted adenosine analogs and their use as antiviral agents | ADAR, ADA, AMPD2 | DYRK1A 3403/4885EGLN1 1609/4885KDM4E 640/4885 |
| US-20200190089-A1 | SMALL MOLECULE INHIBITORS OF NEUTRAL SPHINGOMYELINASE 2 (NSMASE2) FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SMPD2, SPTLC2, SGMS2 | DYRK1A 4576/4885EGLN1 3329/4885KDM4E 1529/4885 |
| US-20060035909-A1 | 2,6,9-trisubstituted 8-azapurines such as 2-(4-aminocyclohexylamino)-6-benzylamino-9-isopropyl-8-azapurine, used as cyclin-dependent kinase inhibitors, in the treatment of skin disorders, viral infections, cancer, arthritis, lupus, diabetes, multiple sclerosis, restenosis, polycystic kidney disease, gout | CDK8, CDK6, CDK1 | DYRK1A 964/4885EGLN1 4739/4885KDM4E 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.